RESUMO
The efficacy of including interferon inductor - meglumine acridone acetate (cycloferon) - into a complex therapy of pre-school-age patients with reactivated Epstein - Barr virus infection in the form of mononucleosis has been assessed. It is established that the use of cycloferon leads to regression of the main clinical-hematological symptoms of disorder during the progression period (with a decrease in the clinical treatment period on the average by 4.39 bed days) and favors smoother course of the restoration period. The maximum effect was achieved using prolonged cycloferon treatment schedule, which led to more pronounced relief of residual phenomena, decreased recurrence frequency, and number of acute respiratory complications as comparted to a short-term treatment and control groups.
